ArticleCureus2025
The Impact of Body Mass Index on Survival and Clinical Outcomes in Pulmonary Arterial Hypertension: Revisiting the Obesity Paradox.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond the Heart-Lung Axis: A Review of the Crosstalk Between the Hemodynamic, Neurohormonal, and Immune Systems in Pulmonary Hypertension.Comprehensive physiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to investigate the impact of body mass index (BMI) on survival outcomes and clinical characteristics in patients with pulmonary arterial hypertension (PAH). Given the conflicting evidence on the "obesity paradox," we sought to further explore this phenomenon within a demographically diverse cohort at Louisiana State University Health Sciences Center in Shreveport. MATERIALS AND
methodsWe conducted a retrospective observational study of PAH patients aged 18 years and older who received care at our institution from 2019 to 2022. Patients were categorized by BMI as normal (<25 kg/m²), overweight (25-30 kg/m²), and obese (>30 kg/m²). Clinical and demographic data, including age, gender, comorbidities, PAH subtype, and functional measures, were collected. Hemodynamic parameters, right heart catheterization (RHC) findings, and functional assessments were also included. Survival analysis was conducted using the Kaplan-Meier method, with group comparisons performed via ANOVA and chi-squared tests.
resultsA total of 69 patients were included, with 55.1% classified as obese, 26.1% as overweight, and 18.8% as having a normal BMI. The majority of patients were female (72%) and African American (44.8%). Although obese patients displayed more severe hemodynamic measures, including higher mean pulmonary artery pressure (mPAP) and greater right ventricular dysfunction, the survival analysis showed that the obese group had a non-significant trend toward better survival outcomes compared to normal BMI and overweight groups. Functional improvements on the 6-minute walk test (6MWT) post-treatment were also more pronounced in the obese group.
conclusionOur findings contribute to the understanding of the obesity paradox in PAH, revealing a potential trend toward improved survival in obese PAH patients despite more adverse hemodynamic profiles. These results underscore the need for further research to elucidate the mechanisms underlying the obesity paradox in PAH and to determine if BMI-targeted management strategies may benefit this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.